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Central Figure. Landmark analyses of the cumulative incidences (with confidence 
intervals) for cardiovascular and non-cardiovascular mortality at different time points in 

















Cardiovascular causes were responsible for the majority of deaths within the first year 
following CABG. Deaths attributed to non-cardiovascular causes gained importance over time 
















Patients who survived the first year after CABG appeared increasingly likely to die from other 
causes than cardiovascular reflecting that the risk of competing diseases increases with age, 
especially in an ageing population. This knowledge will add further to the information 

















Abstract (245 words) 1 
Objectives: Knowledge on the association between time and causes of death following 2 
coronary artery bypass grafting (CABG) is sparse. W examined short-and long-term mortality 3 
and cause of death in patients undergoing CABG. 4 
Methods: Using Danish nationwide registries, we identified all patients undergoing isolated 5 
CABG (1998-2014). Cause of death was classified as cardiovascular or non-cardiovascular 6 
according to death certificates. Landmark analyses of the cumulative incidences of 7 
cardiovascular and non-cardiovascular mortality after 1, 3, and 5 years after CABG were 8 
performed. Multivariable cause-specific Cox regression models were used to evaluate changes 9 
over time in the risk of all-cause, cardiovascular, and non-cardiovascular mortality after 1 and 10 
7 years after CABG, respectively. 11 
Results: Among 37,495 included patients, 12,230 (32.6%) died uring a median follow-up of 12 
7.4 years. Causes of death were classified as cardiov scular in 6459 (52.8%) and non-13 
cardiovascular in 5771 (47.2%) cases. Within the first year, the incidence of cardiovascular 14 
death was higher compared with non-cardiovascular de th (3.9% versus 1.1%,p-value <0.001). 15 
The cumulative incidences of cardiovascular and non-cardiovascular were deaths similar in the 16 
periods 1-3 years (2.3% versus 2.6%,p-value 0.004), 3-5 years (3.1% versus 3.2%,p-value 17 
0.75), and 5-7 years post-surgery (3.7% versus 4.0%,p-value 0.07). The crude rates and 18 
adjusted risks of short- and long-term all-cause and cardiovascular mortality decreased during 19 
the study period despite an increase in age and burden of comorbidities. 20 
Conclusions: In patients undergoing CABG, cardiovascular causes w re responsible for the 21 
majority of deaths within the first year. Deaths attributed to non-cardiovascular causes gained 22 















Introduction  24 
Over the last four decades, revascularization by coronary artery bypass grafting (CABG) has 25 
been a well-recognized treatment to relieve symptoms f angina pectoris and to improve 26 
survival in patients with coronary artery disease (CAD).(1) Short- and long-term mortality has 27 
been investigated in patients undergoing CABG;(2-15) however, studies describing the 28 
association between time and causes of death following CABG are sparse and limited by a 29 
small number of patients or only investigating a subpopulation.(16-21) Evaluating long-term 30 
cause of death in patients undergoing CABG is of great importance in order to enhance 31 
current treatment strategies and secondary prevention programs, thereby aiming to reduce 32 
mortality in the long-term. From a clinical perspective, knowledge on long-term cause of 33 
death will add further to the information provided to the patients at discharge after coronary 34 
revascularization about long-term prospects and life expectancy. In patients with ST-segment 35 
elevation myocardial infarction undergoing primary percutaneous coronary intervention 36 
(PCI), a recent study suggests that cardiovascular de th is prevalent in the acute phase, 37 
whereas non-cardiovascular death gains importance over time.(22) Whether this may be the 38 
case in patients undergoing isolated CABG has yet to be determined. To address this gap in 39 
knowledge, we conducted a nationwide retrospective ohort study to examine short- and long-40 
term mortality and cause of death in patients undergoing isolated CABG. 41 
 42 
Methods 43 
Data sources 44 
The Danish healthcare system, funded by taxes, provides free and equal access to healthcare 45 
for all residents regardless of socioeconomic or insurance status. The assignment of a unique 46 
and permanent civil registration number to all resid nts in Denmark allows accurate linkage 47 
of nationwide administrative registries at an indivi ual level. For this study, we used four 48 















admissions since 1977 and all surgical procedures since 1996. Each admission is registered by 50 
one primary diagnosis and, if appropriate, one or me secondary diagnosis according to the 51 
International Classification of Diseases (ICD-8 until 1993 and ICD-10 from 1994). All 52 
surgical procedures, registered according to the NOMESCO Classification of Surgical 53 
Procedures (NCSP) used in Nordic countries, are registered by one or more codes depending 54 
on the type and scale of the operation.(23) The Danish Registry of Medicinal Product 55 
Statistics contains detailed information on all claimed drug prescriptions dispensed from 56 
pharmacies in Denmark since 1995. The drugs are classified according to the international 57 
Anatomical Therapeutic Chemical (ATC) system with information on dispensing date, 58 
strength, and quantity dispensed.(24) Information on vital status was obtained from the 59 
Danish National Population Registry, in which information on all deaths is registered within 60 
two weeks after their occurrence. Causes of death cl ssified according to the ICD-10 were 61 
obtained from the Danish Registry of Causes of Death.(25) 62 
 63 
Study population, comorbidity, and concomitant pharmacotherapy 64 
We identified all patients undergoing first-time cardi c surgery between January 1, 1998 and 65 
December 31, 2014. To investigate the association between time and cause of death in 66 
patients undergoing first-time isolated CABG, we excluded those who underwent CABG with 67 
concomitant valve or other cardiac surgical procedur s, were younger than 18 years, and were 68 
non-Danish citizens. 69 
Urgency of CABG was classified as either elective surgery, urgent surgery 70 
(defined as surgery performed during the hospitalization period for acute myocardial 71 
infarction (AMI)), or emergency surgery (defined as surgery within 24 h after admission for 72 
AMI or surgery on the same day as PCI). Patient comorbidity was obtained through the 73 
Danish National Patient Registry using hospital discharge diagnoses prior to admission for 74 















hypertension were identified using claimed drug presc iptions as done previously.(26) 76 
Concomitant pharmacotherapy was defined through the Danish Registry of Medicinal Product 77 
Statistics as a claimed prescription within 180 days prior to admission for CABG 78 
(Supplementary Table 2 for ATC codes). 79 
 80 
Causes of death and outcomes 81 
The Danish Registry of Causes of Death holds information about the date, place, and manner 82 
of death (natural, accident, violence, suicide, uncertain) as well as the underlying cause (the 83 
disease or condition which started the process that lead to death) and, if appropriate, one or 84 
more contributory causes.(25) Based on the underlying cause, we classified causes of death 85 
into the following categories: 1) Definite cardiovascular; 2) possible cardiovascular; 3) non-86 
cardiovascular; and 4) unknown (Supplementary Table 3 for ICD-10 codes). Based on these 87 
categories, we further classified causes of death as cardiovascular or non-cardiovascular: The 88 
first and second category was considered a cardiovascul r death, and the remaining categories 89 
were considered a non-cardiovascular death. All-cause mortality, cardiovascular death, and 90 
non-cardiovascular death were used as endpoints in separate analyses. Patients were followed 91 
from the day of surgery until occurrence of the event (cardiovascular and non-cardiovascular 92 
mortality) or the end of the study (December 31, 2014). 93 
 94 
Statistical analyses 95 
Descriptive data were reported as frequencies and percentages or median with 25th and 75th 96 
percentiles as appropriate. Baseline characteristics were summarized separately according to 97 
three time periods in which surgery was performed (i.e. 1998-2003, 2004-2009, and 2010-98 
2014) and differences between groups were tested by appl ing the Cochran-Armitage test for 99 
trend for categorical variables and the Kruskal-Wallis test for continuous variables. 100 















cardiovascular and non-cardiovascular death while taking into account the competing risk of 102 
other causes of death. In addition, landmark analyses of the cumulative incidences of 103 
cardiovascular and non-cardiovascular mortality were performed and compared using cause-104 
specific hazards by the log-rank test; the first analysis covered the first year after CABG, and 105 
additional analyses started on year 1, 3, and 5 and ended 2 years after each time point. The 106 
landmarks were selected a priori based on clinically re evant time points. Multivariable cause-107 
specific Cox proportional hazard regression models w re used to evaluate changes over time 108 
in the risk of all-cause, cardiovascular, and non-cardiovascular mortality after 1 and 7 years 109 
after CABG, respectively. In addition, factors associated with cardiovascular mortality in the 110 
time periods, 0-1 and 1-7 years after CABG, were identified using multivariable cause-111 
specific Cox regression models. All models were adjusted for age, gender, urgency of CABG, 112 
prior PCI, all comorbidities listed in Table 1, and the time period in which surgery was 113 
performed. The proportional hazards assumption was tested and found valid. Clinical relevant 114 
interactions including age, sex, and several comorbidities were tested for and found not 115 
significant, unless otherwise stated. There was no missing data for any of the covariates or 116 
outcomes. All statistical analyses were performed with SAS statistical software (SAS 9.4, 117 
SAS Institute, Cary, North Carolina, USA). A two-sided p-value <0.05 was considered 118 
statistically significant. 119 
 120 
Sensitivity analysis 121 
To test the robustness of our findings, we considere  deaths due to unknown causes a 122 
cardiovascular death. 123 
 124 
Ethics 125 
Approval for this study was obtained by the Danish Data Protection Agency (No. 2007-58-126 















that individuals could not be identified. Retrospective registry-based studies do not require 128 
ethical approval in Denmark. 129 
 130 
Results 131 
A total of 37,495 patients undergoing isolated CABG between January 1, 1998 and December 132 
31, 2014 with no prior cardiac surgery were identified. The median age of the study 133 
population was 66 (25th-75th percentile 59-72) years, and 81% were men. The proporti n of 134 
patients undergoing emergency and urgent surgery was 5.1% and 13.9%, respectively. 135 
Baseline characteristics stratified according to time periods are summarized in Table 1. 136 
Patients who underwent CABG between 2010 and 2014 were older, more often men, more 137 
likely to undergo urgent or emergency surgery and had generally more comorbidities 138 
compared with those who underwent CABG in the period 1998-2003. 139 
 140 
Cause of death 141 
12,230 patients died during a median follow-up of 7.4 years. Cause of death was definite 142 
cardiovascular in 5172 (42.3%), possible cardiovascul r in 1287 (10.5%), non-cardiovascular 143 
in 5320 (43.5%), and unknown in 451 (3.7%) patients. The most common non-cardiovascular 144 
causes of death were cancer and infection accounting for 2808 (23.0%) and 544 (4.5%) of the 145 
total numbers of deaths, respectively. 146 
 147 
Cumulative incidence of death 148 
Figure 1 displays the cumulative incidence curves for all-cause, cardiovascular, and non-149 
cardiovascular mortality. The cumulative incidences of 30-day, 1-year, and 7-year all-cause 150 
mortality were 2.4%, 5.0%, and 21.9%, respectively, and the corresponding cumulative 151 















Results from the landmark analyses of the cumulative incidences of 153 
cardiovascular and non-cardiovascular mortality at 1, 3, 5, and 7 years are shown in Central 154 
Figure/Figure 2. Within the first year after CABG, the incidence of cardiovascular death was 155 
higher compared with non-cardiovascular death (3.9% versus 1.1%, p-value < 0.001). 156 
However, the landmark analyses showed similar cumulative incidences of cardiovascular and 157 
non-cardiovascular deaths in the periods 1-3 years post-surgery (2.3% versus 2.6%, p-value 158 
0.004), 3-5 years post-surgery (3.1% versus 3.2%, p-value 0.75), and 5-7 years post-surgery 159 
(3.7% versus 4.0%, p-value 0.07). 160 
 161 
Time trends 162 
The crude rates and adjusted risks of all-cause, cardiovascular, and non-cardiovascular 163 
mortality according to time of surgery are displayed in Figure 3. The crude rate and adjusted 164 
risk of 1-year all-cause and cardiovascular mortality decreased during the study period, while 165 
the risk of non-cardiovascular mortality did not differ significantly. Likewise, a decrease in 166 
the crude rates and risks of 7-year all-cause and crdiovascular mortality during the study 167 
period were observed. 168 
Concomitant medical treatment one year post-surgery stratified according to 169 
time of surgery is summarized in Supplementary Table 4. A higher proportion of patients who 170 
underwent CABG between 2010 and 2014 were treated with beta-blockers, statins, aspirin, 171 
and renin-angiotensin-system inhibitors) compared with those who underwent CABG in the 172 
period 1998-2003. 173 
 174 
Factors associated with cardiovascular mortality 175 
Results from the multivariate Cox proportional hazard nalysis for 1-year cardiovascular 176 
mortality are presented in Supplementary Figure 1a. Advanced age, female gender, urgency of 177 















Factors associated with cardiovascular mortality in the period, 1-7 years after 179 
CABG are displayed in Supplementary Figure 1b. Advanced age, male gender, and various 180 
comorbidities were associated with long-term cardiovascular mortality. 181 
 182 
Sensitivity analysis 183 
To test the robustness of our findings, deaths due to nknown causes were considered 184 
cardiovascular. This analysis yielded similar results as the main analysis (Supplementary 185 
Figure 2 and 3). 186 
 187 
Discussion 188 
In this nationwide cohort study, we examined short- and long-term mortality and cause of 189 
death in patients undergoing isolated CABG. Our study yielded the following major findings: 190 
First, cardiovascular causes were responsible for the majority of deaths within the first year, 191 
while deaths attributed to non-cardiovascular causes gained importance over time elapsed 192 
since CABG. Second, the crude rates and adjusted risks of short- and long-term all-cause and 193 
cardiovascular mortality decreased during the study period despite an increase in age and 194 
burden of comorbidities. 195 
Previous studies have reported on causes of death following CABG; however, 196 
these studies were limited by including a small number of patients, investigating subgroups 197 
(e.g. patients with heart failure, diabetes, complex CAD etc.), or applying specific inclusion 198 
and exclusion criteria, thus not reflecting patients i  a real-world setting. To our knowledge, 199 
this is the first study to examine short- and long-term causes of death in a large all-comers 200 
cohort of patients undergoing CABG on a nationwide scale. In our cohort, 52.5% of all deaths 201 
during a median follow-up of 7.4 years were attributed to a cardiovascular cause. Another 202 
observational study found that 58% of all deaths (n = 739) in a cohort of 2000 patients with 203 















year follow-up of the randomized Synergy between PCI with Taxus and Cardiac Surgery 205 
(SYNTAX) trial showed, however, that only 49.5% of all deaths in patients treated with 206 
CABG were attributed to a cardiovascular cause. Intrestingly, only patients with complex 207 
CAD were enrolled in the SYNTAX trial, and it could be expected that the proportion of 208 
cardiovascular deaths was even higher in such population. However, the low proportion of 209 
cardiovascular deaths may partly be explained by the quite low number of deaths (n = 97) 210 
during the follow-up period. In the Surgical Treatment for Ischemic Heart Failure (STICH) 211 
trial, 610 patients underwent CABG, and during a median follow-up of 56 months, 218 212 
patients died, of which 74% were considered cardiovascular.(20) The large proportion of 213 
cardiovascular deaths and the high mortality observed in the STICH trial is not surprising as 214 
the study population comprised only patients with ischemic cardiomyopathy with reduced 215 
ejection fraction. 216 
Knowledge of short- and long-term causes of death is crucial in order to 217 
improve treatment strategies and secondary prevention programs. In a recent study, Pedersen 218 
et al. examined the association between time and cause of death in patients with ST-segment 219 
elevation myocardial infarction undergoing primary PCI. Interestingly, the authors found the 220 
incidence of non-cardiac causes of death to be higher than cardiac causes in patients surviving 221 
the first month after revascularization.(22) Our findings are in line with these results: We 222 
found that cardiovascular deaths were frequent during the first year after CABG reflecting 223 
that the surgical procedure itself is associated with short-term cardiovascular mortality. 224 
Patients who survived the first year appeared increasingly likely to die from other causes than 225 
cardiovascular. The risk of competing diseases increases with age, especially in an ageing 226 
population; in line with this, we found that cancer was the most common cause of non-227 
cardiovascular death accounting for 23% of all deaths following CABG. 228 
Our study revealed that that short- and long-term all-cause and cardiovascular 229 















comorbidities. Several explanations may contribute to these findings. Marked progress in 231 
implementing cardiac rehabilitation programs may play a role in the decrease of 232 
cardiovascular mortality. In patients with CHD, exercise-based cardiac rehabilitation provides 233 
important health benefits including reductions in cardiovascular mortality and 234 
hospitalization.(27) In Denmark, cardiac rehabilitation is recommended as integrated care 235 
with individually planned and coherent rehabilitation across sectors from hospital to 236 
municipal; the overall participation rates for patients with coronary heart disease are above 237 
70%, though only a part of the patients fulfill a complete comprehensive program.(28) A 238 
greater adoption to guideline-directed use of medications post-surgery (i.e. beta-blockers, 239 
statins, aspirin, and renin-angiotensin-system inhibitors) may also explain the decrease in 240 
long-term cardiovascular mortality during the study period. Another possible explanation may 241 
be the increased use of arterial grafts. Although the standard method in Denmark is the use of 242 
left internal mammary artery to the left anterior descending artery and a saphenous vein graft 243 
to the remaining vessels, bilateral mammary artery grafts and radial arteries are being 244 
increasingly used. The superior long-term patency of artery grafts compared with vein grafts 245 
is now well-established and mounting evidence support that the superior patency of artery 246 
grafts translate into improved clinical outcomes, including death from cardiovascular 247 
causes.(29) 248 
Studies examining factors associated with long-term cardiovascular mortality 249 
are sparse as focus has mainly been on all-cause mortality.(9, 19) We found that advanced 250 
age, male gender, cardiovascular comorbidities, chronic renal failure, and chronic obstructive 251 
pulmonary disease were associated with cardiovasculr mortality in the period, 1-7 years after 252 
CABG. The main causes of chronic renal failure in western societies are diabetes and 253 
hypertension, both of which are traditional cardiovascular risk factors, and the main cause of 254 















Therefore, chronic renal failure and chronic obstructive pulmonary disease are surrogate 256 
markers for high cardiovascular risk. 257 
 258 
Strengths and limitations 259 
The main strength of this study is the completeness of data in a nationwide unselected cohort 260 
of 37,495 CABG patients followed for a median 7.4 years in a real-world setting. However, 261 
our study has several limitations that need to be acknowledged. The main limitation of this 262 
study is inherent to its observational design. Our results are dependent on the classification of 263 
causes of death. Determining the exact cause of death is  difficult task and is not always 264 
possible. In this study, causes of death were retrieved from the nationwide Danish Registry of 265 
Causes of Death. The quality of the data relies mainly upon the correctness of the physicians’ 266 
notification and the coding in the National Board of Health.(25) Likewise, comorbidities were 267 
defined using hospital discharge diagnoses that may vary in quality. The possibility of a 268 
differential classification bias related to the classification of causes of death (i.e. definite and 269 
possible cardiovascular deaths were considered cardiov scular, and non-cardiovascular deaths 270 
and deaths due to unknown causes were considered non-cardiovascular) cannot be excluded. 271 
However, when deaths due to unknown causes were considered cardiovascular, we found 272 
similar results as the main analysis. We were not able to evaluate the impact of cardiac 273 
rehabilitation, use of artery grafts, or on- or off-pump surgery on cardiovascular deaths. In 274 
addition, we had no information on important clinical parameters such as left ventricular 275 
systolic function, coronary lesions, plasma creatinine levels, body mass index, smoking 276 
habits, and lipid levels; thus, the effect of unmeasured confounders cannot be excluded. 277 
Moreover, the Danish universal health care system as well as the high life expectancy and 278 
socioeconomic status in Denmark may affect the generalizability of our findings. The 279 
prevalence of diabetes in our cohort was little over 20%, which is less frequent than other 280 















applied landmark analyses to estimate the absolute risk of causes of death at different time 282 
points. However, landmark analyses may be limited by the arbitrary selection of the landmark 283 
times. To minimize the impact of this potential limitation, we selected the landmarks a priori 284 
based on clinically relevant time points. In addition, a recognized disadvantage of the 285 
landmark analysis approach is the omission of events occurring earlier to the landmark time, 286 
i.e. entry in the 1-7 year period is conditional on surviving to one year. However, we did 287 
provide data before the landmark time points. Finally, with a large sample size, very small 288 
differences between groups may become statistically significant, although not necessarily 289 
clinically meaningful (i.e. liver disease in this study). 290 
 291 
Conclusion 292 
In patients undergoing first-time isolated CABG, cardiovascular causes were responsible for 293 
the majority of deaths within the first year. Deaths attributed to non-cardiovascular causes 294 
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Figure legends 399 
Figure 1. Cumulative incidence curves for all-cause mortality, cardiovascular mortality, and 400 
non-cardiovascular mortality in patients undergoing CABG. 401 
 402 
Central Figure/Figure 2. Landmark analyses of the cumulative incidences (with confidence 403 
intervals) for cardiovascular and non-cardiovascular mortality at different time points in 404 
patients undergoing CABG. 405 
 406 
Figure 3. Crude rates and adjusted risks of all-cause, cardiovascular, and non-cardiovascular 407 
mortality according to time of surgery in patients undergoing CABG. a) 30-day mortality; b) 408 
1-year mortality; c) 7-year mortality. 409 
 410 

















Period 1 (1998-2003) 
N=16,649 
Period 2 (2004-2009) 
N=12,213 
Period  (2010-2014) 
N=8633 
P-value 
Age (median [25th-75th percentile]) 66 (59-72) 66 (58-72) 67 (60-73) 68 (61-74) < 0.0001 
Male, N (%) 30,037 (80.1) 13,150 (79.0) 9860 (80.7) 7027 (81.4) < 0.0001 
Surgery, N (%)     < 0.0001 
     Elective 30,375 (81.0) 14,593 (87.7) 9715 (79.6) 6067 (70.3)  
     Urgent 5215 (13.9) 1599 (9.6) 1826 (15.0) 1790 (20.7)  
     Emergency 1905 (5.1) 457 (2.7) 672 (5.5) 776 (9.0)  
Prior PCI, N (%) 6462 (17.2) 2080 (12.5) 2404 (19.7) 1978 (22.9) < 0.0001 
Comorbidities, N (%)      
     Myocardial infarction 19,064 (50.8) 8864 (53.2) 6058 (49.6) 4142 (48.0) < 0.0001 
     Heart failure 5398 (14.4) 2225 (13.4) 1846 (15.1) 1327 (15.4) < 0.0001 
     Stroke 2782 (7.4) 1121 (6.7) 936 (7.7) 725 (8.4) < 0.0001 
     Atrial fibrillation 2542 (6.8) 1096 (6.6) 818 (6.7) 628 (7.3) 0.05 
     Hypertension 21,973 (58.6) 9674 (58.1) 7395 (60.6) 4903 (56.8) 0.33 
     Diabetes 6326 (16.9) 2282 (13.7) 2146 (17.6) 1898 (22.0) < 0.0001 
     Peripheral vascular disease 2582 (6.9) 1135 (6.8) 902 (7.4) 546 (6.3) 0.34 
     Malignancy 2947 (7.9) 1067 (6.4) 1015 (8.3) 865 (10.0) < 0.0001 
     Chronic renal failure 676 (1.8) 211 (1.3) 249 (2.0) 216 (2.5) < 0.0001 
     Chronic obstructive pulmonary disease 2234 (6.0) 929 (5.6) 780 (6.4) 525 (6.1) 0.04 
     Liver disease 500 (1.3) 181 (1.1) 183 (1.5) 136 (1.6) < 0.0001 
Concomitant medical treatment, N (%)      
     Statins 23,902 (63.8) 8445 (50.7) 9204 (75.4) 6253 (72.4) < 0.0001 
     Beta-blockers 23,938 (63.8) 11,062 (66.4) 8064 (66.0) 4812 (55.7) < 0.0001 
     Calcium-blockers 13,913 (37.1) 7133 (42.8) 4036 (33.1) 2744 (31.8) < 0.0001 
     Renin-angiotensin-system inhibitors 15,996 (42.7) 5666 (34.0) 5888 (48.2) 4442 (51.5) < 0.0001 
     Thiazide 6179 (16.5) 2628 (15.8) 2253 (18.5) 1298 (15.0) 0.87 
     Loop diuretics 6276 (16.7) 3213 (19.3) 1992 (16.3) 1071 (12.4) < 0.0001 
     Spironolactone 1536 (4.1) 597 (3.6) 577 (4.7) 362 (4.2) < 0.0001 
     Clopidogrel 4444 (11.9) 995 (6.0) 2364 (19.4) 1085 (12.6) < 0.0001 
     Aspirin 25,499 (68.0) 10,833 (65.1) 8829 (72.3) 5837 (67.6) < 0.0001 




























































































Supplementary Table 1. International Classification of Diseases (ICD) 8 and 10 codes for 
comorbidities 
Comorbidity ICD-8 and ICD-10 codes 
Acute myocardial infarction ICD-10: I21, I22 
ICD-8: 410 
 
Heart failure ICD-10: I42, I50, J81, I110, I130, I132 
ICD-8: 425, 428, 4270, 4271 
 
Stroke ICD-10: I60, I61, I63, I64 
ICD-8: 430-434, 436 
 
Atrial fibrillation ICD-10: I48 
ICD-8: 4274 
 
Peripheral vascular disease ICD-10: I70, I74 
ICD-8: 443 
 
Malignancy ICD-10: C00-C97 
ICD-8: 140-209 
 
Chronic renal failure ICD-10: N18, I12, I13, T858, T859, Z992 
ICD-8: 585 
 
Chronic obstructive pulmonary disease ICD-10: J42, J44 
ICD-8: 490-492 
 
Liver disease ICD-10: K70-K77, K704, K766, K711, 
B150, B160, B190 
















Supplementary Table 2. Anatomical Therapeutic Chemical (ATC) classification codes for 
pharmacotherapy 




Calcium channel blockers 
 






C03A, C07B, C07D, C09XA52, C03EA01 
Loop diuretics 
 
































Supplementary Table 3. International Classification of Diseases (ICD) 10 codes for causes of 
death 
Cause of death ICD-10 codes 
Definitive cardiovascular  
Acute rheumatic pericarditis I01.0 
Acute rheumatic endocarditis I01.1 
Acute rheumatic myocarditis I01.2 
Rheumatic myocarditis I09.0 
Rheumatic diseases of endocardium, valve unspecified I09.1 
Chronic rheumatic pericarditis I09.2 
Hypertensive heart disease with (congestive) heart failure I11.0 
Hypertensive heart and renal disease with (congestive) heart failure I13.0 
Hypertensive heart and renal disease with both (congestive) heart 
failure and renal failure 
I13.2 
Acute myocardial infarction I21 
Subsequent myocardial infarction I22 
Certain current complications following acute myocardial infarction I23 
Other acute ischaemic heart diseases I24 
Pulmonary embolism I26 
Acute pericarditis I30 
Other diseases of pericardium I31 
Pericarditis in diseases classified elsewhere I32 
Acute and subacute endocarditis I33 
Endocarditis, valve unspecified I38 
Endocarditis, valve unspecified, in diseases classified elsewhere I39.8 
Acute myocarditis I40 
Myocarditis in diseases classified elsewhere I41 
Cardiomyopathy I42 
Cardiomyopathy in diseases classified elsewhere I43 
Heart failure I50 
Subarachnoid haemorrhage I60 
Intracerebral haemorrhage I61 
Other nontraumatic intracranial haemorrhage I62 
Cerebral infarction I63 
Stroke, not specified as haemorrhage or infarction I64 
Dissection of aorta [any part] I71.0 
Thoracic aortic aneurysm, ruptured I71.1 
Abdominal aortic aneurysm, ruptured I71.3 
Thoracoabdominal aortic aneurysm, ruptured I71.5 
Aortic aneurysm of unspecified site, ruptured I71.8 
Embolism and thrombosis of abdominal aorta I74.0 
Embolism and thrombosis of other and unspecified parts of aorta I74.1 
  
Possible cardiovascular  
















Chronic renal failure and diabetes as comorbidity N18 AND diabetes as comorbidity 
  





Infection A00-B99, J12-J16, J18, J84, J851, 
J852, J86, N10-N12, N30, N390, 
G01-G04, G038, G039, K57, R091 
Respiratory disease J00-J99 (except J12-J16, J18, J84, 
J851, J852, J86) 
Renal disease N00-N99 (except N10-N12, N30) 
















Supplementary Table 4. Concomitant medical treatment one year post-surgery in patients 




Concomitant medical treatment, N (%) 
All patients 
N=33,939 
Period 1 (1998-2003) 
N=15,837 
Period 2 (2004-2009) 
N=11,560 
Period  (2010-2014) 
N=6542 
P-value 
     Statins 27,802 (81.9) 11,238 (71.0) 10,674 (92.3) 5890 (90.0) < 0.0001 
     Beta-blockers 23,322 (68.7) 9516 (60.1) 8861 (76.7) 4945 (75.6) < 0.0001 
     Calcium-blockers 7876 (23.2) 3102 (19.6) 2955 (25.6) 1819 (27.8) < 0.0001 
     Renin-angiotensin-system inhibitors 17,023 (50.2) 6372 (40.2) 6702 (58.0) 3949 (60.4) < 0.0001 
     Thiazide 5161 (15.2) 2395 (15.1) 1955 (16.9) 811 (12.4) < 0.0001 
     Loop diuretics 8534 (25.2) 3928 (24.8) 3057 (26.4) 1549 (23.7) 0.50 
     Spironolactone 2604 (7.7) 1005 (6.4) 985 (8.5) 614 (9.4) < 0.0001 
     Clopidogrel 5163 (15.2) 693 (4.4) 2903 (25.1) 1567 (24.0) < 0.0001 
     Aspirin 27,471 (80.9) 11,756 (74.2) 10,126 (87.6) 5589 (85.4) < 0.0001 














Supplementary Figure 1. Results from the Cox Proportional Hazard analyses examining 
factors associated with cardiovascular mortality in patients undergoing coronary artery 
bypass grafting. a) Within 1 year after CABG; 
 
 
b) In the period, 1-7 years after CABG. 
 
AMI = acute myocardial infarction; PCI = percutaneous coronary intervention; COPD = 














Supplementary Figure 2. Cumulative incidence curves for all-cause mortality, cardiovascular 
mortality (definite cardiovascular, possible cardiovascular, and unknown), and non-
cardiovascular mortality in patients undergoing CABG. 
 
 
Supplementary Figure 3. Landmark analyses of the cumulative incidences (with confidence 
intervals) for cardiovascular (definite cardiovascular, possible cardiovascular, and unknown) 
and non-cardiovascular mortality at different time points in patients undergoing CABG. 
 
